福元医药: 北京福元医药股份有限公司关于盐酸阿莫罗芬搽剂获得药品注册证书的公告

Group 1 - The company, Beijing Fuyuan Pharmaceutical Co., Ltd., has received a drug registration certificate for Amorolfine Hydrochloride Liniment from the National Medical Products Administration [1][2] - The drug is classified as a non-prescription chemical drug and is indicated for the treatment of fungal infections of the nails [2] - The total R&D investment for this drug has reached approximately RMB 3.9783 million (unaudited) as of the announcement date [2] Group 2 - The market data indicates that the sales revenue for Amorolfine Hydrochloride Liniment in China was approximately RMB 456.08 million in 2024, with significant contributions from various healthcare settings [2] - The approval of the drug registration certificate is expected to enhance the company's product line and market competitiveness [2]